Core Viewpoint - XORTX Therapeutics Inc. held its annual and special meeting of shareholders, where all proposed matters were approved, including the election of board members and the appointment of auditors, indicating strong governance and support from shareholders [2][3]. Company Overview - XORTX is a late-stage clinical pharmaceutical company focused on developing therapies for progressive kidney disease, with two advanced products: XRx008 for autosomal dominant polycystic kidney disease (ADPKD) and XRx-101 for acute kidney injury related to COVID-19 [5]. Shareholder Meeting Results - A total of 889,288 common shares were represented at the meeting, accounting for approximately 31% of the total shares outstanding [2]. - All seven management nominees were elected to the board, including Anthony Giovinazzo as Chair and Allen Davidoff as CEO [2][3]. Board Composition - The board now includes two recently appointed directors, Abigail Jenkins and Patrick Treanor, enhancing the company's governance with experienced individuals in biotech and clinical trials [3]. Research and Development - The company has made advancements in its intellectual property portfolio and is conducting pioneering research in ADPKD, which supports its treatment approach and enhances understanding of the disease [4]. - Recent peer-reviewed research has linked genetic factors to kidney disease, potentially broadening therapeutic approaches [4].
XORTX Announces Results of Annual and Special Meeting of Shareholders